TDOC — Teladoc Health, Inc.
Is TDOC overbought or oversold? Here is the current MarketMoodz read.
Teladoc Health, Inc. (TDOC) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Health Information Services) last closed at $8.70. The rating moved from Oversold to Overbought on October 21, 2026.
- Public ratingOverbought (as of November 17, 2026)
- Last close$8.70
- Last changeMoved from Oversold to Overbought on October 21, 2026
- SectorHealthcare
- IndustryHealth Information Services
See all overbought Healthcare stocks →
AI analysis
Teladoc Health, Inc. (TDOC) remains a leader in virtual care with valuable chronic-care data and established payor/employer relationships, but the path to consistent profitability is not yet proven. Revenue growth has been intact, supported by recurring contracts and expanding care offerings, yet margin recovery depends on sustained utilization, tighter cost discipline and successful commercialization of higher‑value services. Near-term headwinds include a cautious market tone, competitive pricing pressure and regulatory uncertainty around reimbursement and Medicare-related programs. Catalysts that could improve outcomes include stronger client retention, scaled partnerships with payors, and demonstrable improvements in free cash flow. Conversely, elevated churn, adverse contract renewals or policy shifts could materially weaken financials. The balance of opportunity and execution risk supports a neutral stance with moderate conviction pending clearer evidence of durable profitability and enrollment/retention stability.
Key factors
- Market-leading telehealth footprint and brand recognition across virtual primary care, urgent care and chronic-care management
- Solid revenue growth history driven by increased utilization and recurring contract relationships with payors and employers, but margin recovery remains incomplete
- Large data asset from chronic-condition management (post-Livongo) that supports cross-sell and higher-value care pathways
- Expanding partnerships with payors and health systems that can drive scale and recurring revenue if retention trends stabilize
- Macroeconomic and market risk environment is cautious, reducing near-term upside for cyclical or growth-exposure healthcare names
- Balance sheet and liquidity have improved versus peak burn periods, but ongoing free-cash-flow generation is marginal and dependent on cost controls and client retention
Risks
- Sustained pricing pressure and reimbursement uncertainty from payors, including possible cuts to telehealth rates or more aggressive contract terms
- High competition from incumbents and well-capitalized entrants (health systems, insurers, digital health specialists) compressing growth and margins
- Regulatory and policy shifts (Medicare/MA program changes) that could alter economics for virtual care or change incentive structures
- Customer concentration and contract churn risk among large enterprise clients that could materially impact near-term revenue
- Execution risk on integration of prior acquisitions and on converting data assets into durable, high-margin services
- Macroeconomic downside or risk-off market flows that reduce enterprise IT and vendor spend in healthcare
- Limited visibility into near-term profitability and the potential need for additional restructuring or capital if utilization/revenue falters
See today's live rating, score and targets
Members see the live hourly rating for TDOC — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.